| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 107 | 2024 | 655 | 19.700 |
Why?
|
| Everolimus | 33 | 2021 | 436 | 5.640 |
Why?
|
| Gastrointestinal Neoplasms | 23 | 2021 | 624 | 4.710 |
Why?
|
| Octreotide | 21 | 2021 | 131 | 4.220 |
Why?
|
| Pancreatic Neoplasms | 56 | 2022 | 5255 | 3.840 |
Why?
|
| Carcinoid Tumor | 25 | 2017 | 282 | 3.650 |
Why?
|
| Malignant Carcinoid Syndrome | 11 | 2021 | 40 | 2.880 |
Why?
|
| Carcinoma, Neuroendocrine | 13 | 2024 | 743 | 2.830 |
Why?
|
| Sirolimus | 15 | 2013 | 831 | 2.740 |
Why?
|
| Antineoplastic Agents, Hormonal | 12 | 2021 | 841 | 2.350 |
Why?
|
| Stomach Neoplasms | 43 | 2023 | 2330 | 2.040 |
Why?
|
| Antineoplastic Agents | 36 | 2021 | 14616 | 1.710 |
Why?
|
| Liver Neoplasms | 26 | 2024 | 4820 | 1.610 |
Why?
|
| Insulinoma | 7 | 2019 | 53 | 1.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 41 | 2023 | 16669 | 1.330 |
Why?
|
| Clinical Trials, Phase II as Topic | 7 | 2015 | 690 | 1.270 |
Why?
|
| Clinical Trials, Phase III as Topic | 9 | 2021 | 500 | 1.250 |
Why?
|
| TOR Serine-Threonine Kinases | 15 | 2017 | 1564 | 1.210 |
Why?
|
| Bevacizumab | 12 | 2022 | 967 | 1.170 |
Why?
|
| Carcinoma, Islet Cell | 5 | 2008 | 35 | 1.170 |
Why?
|
| Humans | 236 | 2024 | 270744 | 1.070 |
Why?
|
| Neovascularization, Pathologic | 13 | 2017 | 1585 | 1.030 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 417 | 1.010 |
Why?
|
| Chromogranin A | 4 | 2016 | 67 | 0.960 |
Why?
|
| Aged | 107 | 2024 | 73375 | 0.960 |
Why?
|
| Lutetium | 1 | 2024 | 5 | 0.940 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2021 | 2651 | 0.920 |
Why?
|
| Phosphopyruvate Hydratase | 3 | 2014 | 88 | 0.910 |
Why?
|
| Male | 139 | 2024 | 128374 | 0.900 |
Why?
|
| Middle Aged | 120 | 2024 | 90334 | 0.870 |
Why?
|
| Hypoglycemia | 2 | 2019 | 220 | 0.870 |
Why?
|
| Radioisotopes | 1 | 2024 | 178 | 0.860 |
Why?
|
| Research Design | 7 | 2019 | 1569 | 0.850 |
Why?
|
| Intestinal Neoplasms | 5 | 2021 | 205 | 0.840 |
Why?
|
| Angiogenesis Inhibitors | 11 | 2021 | 1267 | 0.840 |
Why?
|
| Female | 144 | 2024 | 148945 | 0.840 |
Why?
|
| Immunosuppressive Agents | 5 | 2013 | 1429 | 0.830 |
Why?
|
| Somatostatin | 3 | 2014 | 122 | 0.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 13 | 2023 | 1579 | 0.830 |
Why?
|
| Sp1 Transcription Factor | 12 | 2010 | 193 | 0.830 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2024 | 2175 | 0.780 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 45 | 0.750 |
Why?
|
| Disease-Free Survival | 26 | 2018 | 10260 | 0.730 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.730 |
Why?
|
| SEER Program | 10 | 2019 | 1047 | 0.720 |
Why?
|
| Biomarkers, Tumor | 22 | 2024 | 10706 | 0.720 |
Why?
|
| Clinical Trials as Topic | 13 | 2019 | 3845 | 0.710 |
Why?
|
| Chemoembolization, Therapeutic | 6 | 2017 | 192 | 0.710 |
Why?
|
| Health Expenditures | 2 | 2022 | 202 | 0.690 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2024 | 7784 | 0.690 |
Why?
|
| Drug Costs | 1 | 2021 | 140 | 0.690 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2019 | 361 | 0.660 |
Why?
|
| Treatment Outcome | 47 | 2022 | 33733 | 0.650 |
Why?
|
| Adult | 87 | 2024 | 81975 | 0.650 |
Why?
|
| Perfusion Imaging | 2 | 2018 | 32 | 0.640 |
Why?
|
| Lung Neoplasms | 10 | 2022 | 12028 | 0.630 |
Why?
|
| Diarrhea | 4 | 2017 | 716 | 0.630 |
Why?
|
| Quality of Life | 9 | 2023 | 4775 | 0.610 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2021 | 6255 | 0.610 |
Why?
|
| Aged, 80 and over | 43 | 2024 | 31006 | 0.600 |
Why?
|
| PPAR delta | 3 | 2023 | 53 | 0.600 |
Why?
|
| Prognosis | 42 | 2024 | 22480 | 0.600 |
Why?
|
| Survival Analysis | 25 | 2017 | 9290 | 0.600 |
Why?
|
| Radiopharmaceuticals | 4 | 2021 | 1341 | 0.560 |
Why?
|
| Body Weight | 2 | 2021 | 1311 | 0.550 |
Why?
|
| Organometallic Compounds | 4 | 2021 | 209 | 0.550 |
Why?
|
| Cell Differentiation | 7 | 2015 | 4117 | 0.550 |
Why?
|
| Tumor Burden | 6 | 2018 | 2033 | 0.540 |
Why?
|
| Coordination Complexes | 1 | 2016 | 17 | 0.530 |
Why?
|
| Double-Blind Method | 12 | 2023 | 2588 | 0.520 |
Why?
|
| Adenocarcinoma | 24 | 2023 | 7915 | 0.520 |
Why?
|
| Proportional Hazards Models | 14 | 2024 | 5102 | 0.510 |
Why?
|
| Liver | 5 | 2020 | 3089 | 0.510 |
Why?
|
| Medical Oncology | 7 | 2018 | 1465 | 0.510 |
Why?
|
| Ileal Neoplasms | 6 | 2013 | 49 | 0.510 |
Why?
|
| Patient Selection | 7 | 2020 | 2026 | 0.500 |
Why?
|
| Neoplasms | 12 | 2024 | 15919 | 0.480 |
Why?
|
| Fluorouracil | 14 | 2021 | 1989 | 0.470 |
Why?
|
| Carcinoma | 8 | 2015 | 2609 | 0.470 |
Why?
|
| Carcinoma, Large Cell | 1 | 2014 | 98 | 0.460 |
Why?
|
| Combined Modality Therapy | 16 | 2017 | 9039 | 0.460 |
Why?
|
| Injections, Intramuscular | 2 | 2015 | 247 | 0.450 |
Why?
|
| Survival Rate | 24 | 2021 | 12526 | 0.450 |
Why?
|
| United States | 23 | 2021 | 15853 | 0.450 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 147 | 0.450 |
Why?
|
| Interferon-alpha | 4 | 2017 | 959 | 0.440 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 1642 | 0.440 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 661 | 0.430 |
Why?
|
| Neoplasm Grading | 7 | 2017 | 1822 | 0.430 |
Why?
|
| Consensus | 6 | 2021 | 1104 | 0.430 |
Why?
|
| Health Services | 1 | 2013 | 100 | 0.420 |
Why?
|
| Streptozocin | 4 | 2021 | 70 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2021 | 4961 | 0.420 |
Why?
|
| Neoplasm Staging | 34 | 2017 | 14012 | 0.410 |
Why?
|
| Duodenal Neoplasms | 4 | 2007 | 138 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 6 | 2014 | 2399 | 0.390 |
Why?
|
| Hepatic Artery | 3 | 2013 | 256 | 0.390 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 427 | 0.380 |
Why?
|
| Drug Therapy | 1 | 2012 | 205 | 0.370 |
Why?
|
| Mutation | 8 | 2024 | 15911 | 0.370 |
Why?
|
| Biopsy | 4 | 2024 | 3483 | 0.370 |
Why?
|
| Alanine | 1 | 2011 | 247 | 0.360 |
Why?
|
| Bronchial Neoplasms | 1 | 2011 | 82 | 0.360 |
Why?
|
| Triazines | 1 | 2011 | 122 | 0.360 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2017 | 199 | 0.360 |
Why?
|
| Retrospective Studies | 36 | 2022 | 39827 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 7 | 2015 | 4480 | 0.360 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 1013 | 0.360 |
Why?
|
| Dopamine Antagonists | 1 | 2010 | 61 | 0.350 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 5 | 2017 | 143 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2017 | 1710 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2022 | 3408 | 0.350 |
Why?
|
| Guidelines as Topic | 4 | 2013 | 360 | 0.340 |
Why?
|
| Digestive System Neoplasms | 3 | 2021 | 78 | 0.340 |
Why?
|
| Pyrimidines | 6 | 2020 | 3667 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2021 | 5070 | 0.330 |
Why?
|
| Young Adult | 24 | 2021 | 22216 | 0.330 |
Why?
|
| Rectal Neoplasms | 4 | 2023 | 1240 | 0.330 |
Why?
|
| Incidence | 7 | 2019 | 5825 | 0.330 |
Why?
|
| Esophagogastric Junction | 7 | 2010 | 557 | 0.320 |
Why?
|
| Drug Administration Schedule | 12 | 2017 | 3530 | 0.320 |
Why?
|
| Vipoma | 3 | 2014 | 18 | 0.320 |
Why?
|
| Circulating Tumor DNA | 2 | 2024 | 275 | 0.310 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 1101 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 2073 | 0.300 |
Why?
|
| Esophageal Neoplasms | 12 | 2013 | 3240 | 0.290 |
Why?
|
| Protein Kinases | 6 | 2009 | 903 | 0.290 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 3707 | 0.290 |
Why?
|
| Research Report | 2 | 2018 | 136 | 0.280 |
Why?
|
| Microspheres | 1 | 2008 | 238 | 0.280 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 919 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 10385 | 0.280 |
Why?
|
| Patient Care Team | 1 | 2012 | 822 | 0.280 |
Why?
|
| Doxorubicin | 5 | 2021 | 3145 | 0.280 |
Why?
|
| Immunohistochemistry | 18 | 2019 | 7665 | 0.280 |
Why?
|
| Time Factors | 11 | 2021 | 13021 | 0.270 |
Why?
|
| Drug Design | 1 | 2008 | 371 | 0.270 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 3028 | 0.270 |
Why?
|
| Yttrium Radioisotopes | 1 | 2008 | 210 | 0.260 |
Why?
|
| Disease Progression | 10 | 2015 | 6855 | 0.260 |
Why?
|
| Jejunal Neoplasms | 2 | 2013 | 32 | 0.260 |
Why?
|
| Pancreas | 4 | 2022 | 744 | 0.260 |
Why?
|
| Blood Flow Velocity | 4 | 2015 | 542 | 0.260 |
Why?
|
| Gene Targeting | 1 | 2007 | 314 | 0.260 |
Why?
|
| Plicamycin | 4 | 2010 | 29 | 0.250 |
Why?
|
| Thymus Neoplasms | 1 | 2010 | 416 | 0.250 |
Why?
|
| Chemoradiotherapy | 3 | 2021 | 2027 | 0.240 |
Why?
|
| Medicare | 4 | 2019 | 926 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2023 | 261 | 0.240 |
Why?
|
| Pancreatectomy | 3 | 2019 | 696 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2014 | 9041 | 0.230 |
Why?
|
| Gastrinoma | 3 | 2014 | 25 | 0.230 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 5310 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2024 | 13414 | 0.230 |
Why?
|
| Brachytherapy | 2 | 2008 | 1005 | 0.230 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 87 | 0.230 |
Why?
|
| Docosahexaenoic Acids | 1 | 2024 | 81 | 0.220 |
Why?
|
| Pyrroles | 3 | 2013 | 589 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2018 | 4001 | 0.220 |
Why?
|
| Health Care Costs | 3 | 2022 | 699 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 3 | 2021 | 558 | 0.220 |
Why?
|
| Digestive System | 2 | 2007 | 121 | 0.220 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2024 | 95 | 0.220 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 4328 | 0.220 |
Why?
|
| Ligands | 2 | 2022 | 1016 | 0.220 |
Why?
|
| Piperazines | 3 | 2014 | 2145 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5778 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2023 | 1436 | 0.210 |
Why?
|
| Preoperative Care | 7 | 2018 | 1565 | 0.210 |
Why?
|
| Molecular Imaging | 2 | 2021 | 186 | 0.200 |
Why?
|
| Indoles | 3 | 2013 | 1028 | 0.200 |
Why?
|
| Glucagonoma | 2 | 2014 | 12 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 4374 | 0.200 |
Why?
|
| Estrogens | 2 | 2017 | 809 | 0.200 |
Why?
|
| Forecasting | 3 | 2016 | 702 | 0.200 |
Why?
|
| Databases, Factual | 4 | 2021 | 2251 | 0.200 |
Why?
|
| Age Distribution | 2 | 2017 | 725 | 0.190 |
Why?
|
| Drug Packaging | 1 | 2021 | 13 | 0.190 |
Why?
|
| Deductibles and Coinsurance | 1 | 2021 | 10 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 98 | 0.190 |
Why?
|
| Endocrine Gland Neoplasms | 2 | 2014 | 43 | 0.190 |
Why?
|
| Private Sector | 1 | 2021 | 31 | 0.190 |
Why?
|
| Mice, Nude | 10 | 2012 | 4329 | 0.190 |
Why?
|
| Benzofurans | 1 | 2021 | 40 | 0.190 |
Why?
|
| Gastrectomy | 3 | 2008 | 476 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2010 | 2271 | 0.180 |
Why?
|
| Gastrins | 2 | 2017 | 55 | 0.180 |
Why?
|
| Blotting, Western | 10 | 2010 | 3588 | 0.180 |
Why?
|
| Glucagon | 2 | 2017 | 201 | 0.180 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 15210 | 0.180 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 248 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2020 | 632 | 0.170 |
Why?
|
| Boron Compounds | 1 | 2020 | 69 | 0.170 |
Why?
|
| Animals | 22 | 2024 | 62045 | 0.170 |
Why?
|
| DNA Methylation | 5 | 2016 | 2767 | 0.170 |
Why?
|
| Cell Line, Tumor | 16 | 2012 | 14838 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2017 | 218 | 0.170 |
Why?
|
| Delayed-Action Preparations | 4 | 2017 | 190 | 0.170 |
Why?
|
| Lichenoid Eruptions | 1 | 2019 | 37 | 0.160 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 4963 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6237 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2011 | 2394 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2007 | 1714 | 0.160 |
Why?
|
| Cost of Illness | 2 | 2012 | 504 | 0.160 |
Why?
|
| Gastric Mucosa | 7 | 2009 | 660 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 494 | 0.160 |
Why?
|
| ras Proteins | 2 | 2017 | 804 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2012 | 12102 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 489 | 0.160 |
Why?
|
| Genome, Human | 3 | 2016 | 1886 | 0.160 |
Why?
|
| Registries | 3 | 2019 | 2209 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2020 | 1933 | 0.150 |
Why?
|
| Metabolomics | 1 | 2022 | 504 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2018 | 179 | 0.150 |
Why?
|
| Cisplatin | 12 | 2017 | 2496 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 5403 | 0.150 |
Why?
|
| Glycine | 1 | 2020 | 319 | 0.150 |
Why?
|
| Allelic Imbalance | 2 | 2008 | 41 | 0.150 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 317 | 0.150 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 2007 | 7 | 0.140 |
Why?
|
| Lymphatic Metastasis | 13 | 2018 | 4963 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 965 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2019 | 271 | 0.140 |
Why?
|
| Monocytes | 1 | 2021 | 790 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 103 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2022 | 759 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2022 | 2422 | 0.140 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 1568 | 0.140 |
Why?
|
| Camptothecin | 3 | 2017 | 540 | 0.140 |
Why?
|
| Imatinib Mesylate | 3 | 2014 | 1691 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 1280 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 6 | 2018 | 5231 | 0.140 |
Why?
|
| Glypicans | 1 | 2016 | 50 | 0.140 |
Why?
|
| Genomics | 2 | 2019 | 2836 | 0.140 |
Why?
|
| Goblet Cells | 1 | 2007 | 121 | 0.140 |
Why?
|
| Angiogenic Proteins | 1 | 2016 | 39 | 0.140 |
Why?
|
| Societies, Medical | 3 | 2018 | 1320 | 0.130 |
Why?
|
| Texas | 3 | 2017 | 6447 | 0.130 |
Why?
|
| Risk Factors | 9 | 2021 | 17896 | 0.130 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 281 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 165 | 0.130 |
Why?
|
| Neutrophils | 1 | 2021 | 873 | 0.130 |
Why?
|
| Quinazolines | 1 | 2021 | 956 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 3656 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2021 | 558 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 1335 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2021 | 1275 | 0.130 |
Why?
|
| Tamoxifen | 1 | 1999 | 875 | 0.130 |
Why?
|
| Benzamides | 3 | 2014 | 1879 | 0.130 |
Why?
|
| Publication Bias | 1 | 2015 | 37 | 0.130 |
Why?
|
| Psychometrics | 1 | 2020 | 971 | 0.130 |
Why?
|
| Smad4 Protein | 1 | 2016 | 201 | 0.130 |
Why?
|
| Liver Circulation | 1 | 2015 | 36 | 0.130 |
Why?
|
| Down-Regulation | 4 | 2017 | 2091 | 0.130 |
Why?
|
| Genes, p16 | 2 | 2005 | 132 | 0.120 |
Why?
|
| Probability | 2 | 2015 | 886 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 452 | 0.120 |
Why?
|
| Mice | 16 | 2023 | 35594 | 0.120 |
Why?
|
| Blood Glucose | 2 | 2010 | 1271 | 0.120 |
Why?
|
| Endosonography | 2 | 2011 | 551 | 0.120 |
Why?
|
| Appendiceal Neoplasms | 1 | 2007 | 251 | 0.120 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 3346 | 0.120 |
Why?
|
| Drug Synergism | 4 | 2011 | 1359 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2007 | 374 | 0.120 |
Why?
|
| Serotonin Antagonists | 1 | 2014 | 50 | 0.120 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 1442 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 403 | 0.120 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 670 | 0.120 |
Why?
|
| Thrombectomy | 1 | 2015 | 167 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1089 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 870 | 0.120 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 654 | 0.110 |
Why?
|
| Phenylalanine | 1 | 2014 | 166 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2014 | 149 | 0.110 |
Why?
|
| Skin | 1 | 2019 | 1273 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2015 | 182 | 0.110 |
Why?
|
| Buttocks | 1 | 2013 | 14 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2014 | 4645 | 0.110 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 414 | 0.110 |
Why?
|
| Capecitabine | 3 | 2022 | 390 | 0.110 |
Why?
|
| Insulin | 1 | 2019 | 1486 | 0.110 |
Why?
|
| Blood Volume | 1 | 2013 | 107 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2018 | 527 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 347 | 0.110 |
Why?
|
| Portal Vein | 1 | 2015 | 364 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2359 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2012 | 28 | 0.100 |
Why?
|
| Medical Records | 4 | 2008 | 442 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 16205 | 0.100 |
Why?
|
| Flushing | 1 | 2012 | 7 | 0.100 |
Why?
|
| Epigenomics | 1 | 2014 | 273 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 898 | 0.100 |
Why?
|
| Drug Approval | 1 | 2013 | 174 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 1054 | 0.100 |
Why?
|
| Paclitaxel | 5 | 2006 | 2101 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 2344 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 324 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2022 | 2929 | 0.100 |
Why?
|
| Veins | 1 | 2012 | 165 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 380 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 410 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 1064 | 0.100 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 1604 | 0.100 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 532 | 0.100 |
Why?
|
| Angiography | 2 | 2015 | 350 | 0.100 |
Why?
|
| Adolescent | 11 | 2021 | 32735 | 0.090 |
Why?
|
| Tegafur | 4 | 2007 | 51 | 0.090 |
Why?
|
| Carcinogenesis | 3 | 2023 | 1033 | 0.090 |
Why?
|
| Cells | 1 | 2011 | 38 | 0.090 |
Why?
|
| Inflammation | 1 | 2021 | 2518 | 0.090 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 69 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2019 | 1697 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 1828 | 0.090 |
Why?
|
| Endostatins | 1 | 2010 | 48 | 0.090 |
Why?
|
| Logistic Models | 3 | 2012 | 3448 | 0.090 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2010 | 24 | 0.090 |
Why?
|
| Abdomen | 1 | 2012 | 349 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 510 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2011 | 1710 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 400 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 2573 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 511 | 0.090 |
Why?
|
| Loss of Heterozygosity | 3 | 2008 | 623 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 529 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2010 | 139 | 0.090 |
Why?
|
| Catheter Ablation | 3 | 2017 | 575 | 0.080 |
Why?
|
| Prevalence | 1 | 2017 | 3401 | 0.080 |
Why?
|
| Informed Consent | 1 | 2012 | 416 | 0.080 |
Why?
|
| Checklist | 1 | 2010 | 126 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 1097 | 0.080 |
Why?
|
| Data Accuracy | 2 | 2019 | 45 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 1379 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2012 | 4943 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2009 | 1428 | 0.080 |
Why?
|
| Delphi Technique | 1 | 2010 | 274 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 742 | 0.080 |
Why?
|
| Molecular Chaperones | 2 | 2006 | 266 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2007 | 189 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1884 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2016 | 1208 | 0.080 |
Why?
|
| Receptors, Somatostatin | 1 | 2008 | 94 | 0.080 |
Why?
|
| Adenoma, Islet Cell | 1 | 2008 | 25 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 689 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2009 | 1609 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 1035 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2017 | 275 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2014 | 351 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2008 | 91 | 0.070 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 5002 | 0.070 |
Why?
|
| raf Kinases | 1 | 2008 | 80 | 0.070 |
Why?
|
| Contrast Media | 2 | 2012 | 1499 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2006 | 277 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2012 | 5921 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2004 | 1752 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 637 | 0.070 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2009 | 180 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3478 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 5 | 2022 | 3215 | 0.070 |
Why?
|
| Internet | 1 | 2012 | 691 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 248 | 0.070 |
Why?
|
| Comorbidity | 1 | 2014 | 2392 | 0.070 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2007 | 69 | 0.070 |
Why?
|
| Alu Elements | 1 | 2007 | 89 | 0.070 |
Why?
|
| Genes, abl | 1 | 2007 | 119 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2007 | 104 | 0.070 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2007 | 154 | 0.070 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 109 | 0.070 |
Why?
|
| Dacarbazine | 2 | 2022 | 502 | 0.070 |
Why?
|
| Etoposide | 2 | 2017 | 907 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 2161 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.070 |
Why?
|
| Lymphokines | 1 | 2007 | 313 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2008 | 352 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 334 | 0.070 |
Why?
|
| Macrolides | 1 | 2006 | 65 | 0.070 |
Why?
|
| Chromosome Aberrations | 3 | 2008 | 2031 | 0.070 |
Why?
|
| Indazoles | 2 | 2020 | 310 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 5 | 2010 | 2455 | 0.060 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2005 | 26 | 0.060 |
Why?
|
| Hepatectomy | 2 | 2017 | 1015 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 470 | 0.060 |
Why?
|
| Placebos | 2 | 2017 | 443 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 2238 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5860 | 0.060 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 442 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 799 | 0.060 |
Why?
|
| Esophagectomy | 3 | 2004 | 946 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 566 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 2062 | 0.060 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 11 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 979 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 330 | 0.060 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 142 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 600 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2008 | 520 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 484 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 960 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2012 | 2311 | 0.060 |
Why?
|
| Ethanol | 1 | 2006 | 271 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2009 | 480 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2006 | 196 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1265 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 5589 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 1437 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 325 | 0.060 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2024 | 92 | 0.060 |
Why?
|
| Family | 1 | 2008 | 784 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2012 | 3919 | 0.060 |
Why?
|
| Receptors, CCR6 | 1 | 2023 | 24 | 0.060 |
Why?
|
| Chemokine CCL20 | 1 | 2023 | 39 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2012 | 336 | 0.050 |
Why?
|
| Trifluridine | 1 | 2023 | 28 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 894 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1946 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 2618 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1457 | 0.050 |
Why?
|
| Models, Biological | 1 | 2012 | 3194 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 628 | 0.050 |
Why?
|
| Age of Onset | 1 | 2005 | 853 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 4048 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 6768 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 5171 | 0.050 |
Why?
|
| Uridine Diphosphate Glucose | 1 | 2022 | 6 | 0.050 |
Why?
|
| Oxypurinol | 1 | 2022 | 6 | 0.050 |
Why?
|
| CpG Islands | 1 | 2005 | 671 | 0.050 |
Why?
|
| Oxonic Acid | 3 | 2007 | 24 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2022 | 222 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4497 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2019 | 1712 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 76 | 0.050 |
Why?
|
| Societies | 1 | 2021 | 38 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 521 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 147 | 0.050 |
Why?
|
| Indians, North American | 1 | 2002 | 89 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 382 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 9473 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3031 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 859 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 239 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2007 | 1902 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2005 | 5440 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2010 | 7237 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2008 | 1564 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2008 | 5759 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 354 | 0.040 |
Why?
|
| Proteomics | 1 | 2008 | 1427 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2006 | 1195 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 236 | 0.040 |
Why?
|
| Uracil | 1 | 2000 | 66 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2022 | 295 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2016 | 729 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 2450 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 605 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 563 | 0.040 |
Why?
|
| Drug Combinations | 3 | 2007 | 634 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2002 | 667 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 1042 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 214 | 0.040 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 676 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 485 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 722 | 0.040 |
Why?
|
| Mitomycin | 1 | 2000 | 213 | 0.040 |
Why?
|
| Smoking | 1 | 2008 | 2555 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 95 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 439 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2008 | 1302 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 1312 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 6192 | 0.040 |
Why?
|
| Publications | 1 | 2018 | 54 | 0.040 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 473 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2005 | 1624 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2022 | 784 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2014 | 907 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 7894 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 2357 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5060 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 69 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2022 | 447 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2017 | 79 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 153 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 73 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2011 | 5697 | 0.040 |
Why?
|
| Anal Canal | 1 | 2017 | 236 | 0.030 |
Why?
|
| Pancreatic Polypeptide | 1 | 2016 | 16 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2007 | 201 | 0.030 |
Why?
|
| Methotrexate | 1 | 2000 | 1025 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 274 | 0.030 |
Why?
|
| Sex Factors | 1 | 2002 | 2184 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 205 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2005 | 2319 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 1246 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2006 | 162 | 0.030 |
Why?
|
| RNA, Small Interfering | 3 | 2007 | 2196 | 0.030 |
Why?
|
| Pelvis | 1 | 2017 | 381 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1655 | 0.030 |
Why?
|
| Niacinamide | 1 | 2017 | 428 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 864 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 480 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1401 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2006 | 726 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2007 | 257 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2014 | 35 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 540 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 213 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2007 | 413 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2014 | 6398 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2826 | 0.030 |
Why?
|
| Carboplatin | 1 | 2017 | 880 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2007 | 8696 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 206 | 0.030 |
Why?
|
| Child | 3 | 2018 | 30538 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 600 | 0.030 |
Why?
|
| Piperidines | 1 | 2019 | 1098 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2014 | 118 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 2005 | 639 | 0.030 |
Why?
|
| Remission Induction | 2 | 2013 | 3652 | 0.030 |
Why?
|
| Mesentery | 1 | 2013 | 74 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 1554 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 5149 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 347 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 3900 | 0.030 |
Why?
|
| North America | 1 | 2013 | 337 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 437 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 806 | 0.020 |
Why?
|
| Infant | 1 | 2007 | 13985 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 69 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 104 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2007 | 17043 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2011 | 83 | 0.020 |
Why?
|
| Cecum | 1 | 2010 | 31 | 0.020 |
Why?
|
| Protein Binding | 2 | 2010 | 3485 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2012 | 232 | 0.020 |
Why?
|
| Appendix | 1 | 2010 | 45 | 0.020 |
Why?
|
| ortho-Aminobenzoates | 1 | 2010 | 20 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 622 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 78 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1470 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 692 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2011 | 2846 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2007 | 1347 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 129 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 273 | 0.020 |
Why?
|
| Ileum | 1 | 2010 | 167 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 397 | 0.020 |
Why?
|
| DNA, Neoplasm | 2 | 2005 | 1958 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 498 | 0.020 |
Why?
|
| Jejunum | 1 | 2010 | 228 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2010 | 152 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 1089 | 0.020 |
Why?
|
| Phenotype | 3 | 2005 | 6516 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1389 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 175 | 0.020 |
Why?
|
| Gene Expression | 2 | 2007 | 3642 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 507 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1060 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 487 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 1825 | 0.020 |
Why?
|
| Pyridines | 2 | 2006 | 1311 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 181 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2008 | 54 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 607 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2008 | 135 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2010 | 417 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 235 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2008 | 184 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2007 | 72 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2012 | 602 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2007 | 101 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 757 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2170 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1050 | 0.020 |
Why?
|
| Bryostatins | 1 | 2006 | 14 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1189 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 68 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2005 | 2100 | 0.020 |
Why?
|
| Serotonin | 1 | 2007 | 287 | 0.020 |
Why?
|
| Duodenoscopy | 1 | 2005 | 21 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 1015 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2007 | 288 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2009 | 352 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2009 | 730 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2006 | 3078 | 0.020 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2005 | 31 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 545 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 589 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 461 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 1236 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 506 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 210 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2005 | 206 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 879 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 1496 | 0.010 |
Why?
|
| Floxuridine | 1 | 2003 | 41 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 277 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 1838 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 751 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 7383 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 848 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 589 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2005 | 651 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 985 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 679 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2011 | 2165 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2008 | 1137 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1049 | 0.010 |
Why?
|
| Depression | 1 | 2012 | 1732 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 522 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 462 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 2351 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 1320 | 0.010 |
Why?
|
| Cadherins | 1 | 2005 | 657 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2005 | 706 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 655 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1174 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 1381 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 2474 | 0.010 |
Why?
|
| Apoptosis | 2 | 2005 | 7754 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2122 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 3341 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 728 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 5437 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 3118 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 1857 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2222 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2005 | 2137 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 6686 | 0.010 |
Why?
|
| Recurrence | 1 | 2007 | 4875 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2001 | 366 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 1136 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 1469 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2005 | 1335 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 3063 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1582 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 7103 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 4001 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 5465 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 3051 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 1857 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3439 | 0.010 |
Why?
|
| Palliative Care | 1 | 2003 | 2178 | 0.010 |
Why?
|